By: IPP Bureau
Last updated : April 17, 2026 3:21 pm
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
OpenAI has intensified its push into the pharmaceutical sector with the launch of GPT-Rosalind, a purpose-built artificial intelligence model designed to transform drug discovery and life sciences research workflows.
Announced on April 16, 2026, the model is engineered to support complex scientific tasks including biochemistry, protein engineering, genomics, and translational medicine. GPT-Rosalind aims to significantly compress traditional drug development timelines—often spanning 10–15 years—by accelerating early-stage research and hypothesis generation.
The model integrates advanced capabilities such as multi-step reasoning, experimental planning, and evidence synthesis, while also connecting to over 50 specialised scientific tools and datasets through a dedicated Life Sciences plugin. It is being made available as a research preview via ChatGPT, Codex, and API access for qualified enterprise users.
OpenAI has already secured collaborations with leading pharmaceutical and biotech players including Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific, signaling strong early adoption across the industry.
The move underscores a broader strategic shift by OpenAI toward high-value enterprise applications, particularly in sectors like healthcare and pharmaceuticals where AI can unlock significant productivity gains. As demand grows for AI-driven drug discovery tools, GPT-Rosalind positions OpenAI at the forefront of the emerging convergence between artificial intelligence and life sciences innovation.